Background: Adenocarcinoma of the proximal esophagus is a rare clinical entity, with only 28 cases described in the literature. We report our experience with 9 patients and a review of the literature on this topic.
Methods: Between 1980 and 2004, 1010 patients with esophageal or gastroesophageal junction adenocarcinoma (from a total of 4655 cancers, 3510 squamous and 1145 adeno) presenting at our department were retrospectively evaluated.
Results: Nine patients (0.9%) had adenocarcinoma located in the proximal esophagus. Four patients (Group A) were considered unfit for surgery due to severe comorbidities and/or advanced stage disease. Three of them received endoscopic yttrium-aluminum-garnet (YAG)-laser therapy; 1 patient had feeding gastrostomy. Their median survival was 6 months (range, 3-9 months). The other 5 patients (Group B) were given a first-line cytoreductive treatment: 4 had complete response, and 1 patient did not complete chemotherapy due to toxicity and underwent surgery for residual disease. The median survival for these 5 patients receiving cytoreductive therapy was 36 months (range, 24-132 months). For the 4 patients with complete clinical response to cytoreductive treatment, the median survival was 54 months (range, 24-132 months).
Conclusion: First-line chemoradiotherapy is an effective treatment for adenocarcinoma of the proximal esophagus. Salvage surgery may be reserved for patients with incomplete response or recurrent disease.